Table 2.
Multiple linear regression models estimating the average change in CD4 cell count per month (CD4 slope). Separate models analyse the first (0 – 16 weeks) and second (16 – 48 weeks) phases of immune recovery during ART.
| Phase 1 (0–16 weeks) CD4 slope (n = 596) | Phase 2 (16–48 weeks) CD4 slope (n = 311)1 | ||||||
| Mean | (95% CI) | P value | Mean | (95% CI) | P value | ||
| Age (years) | <30 | 1.0 | 1.0 | ||||
| 30–39 | -2,27 | (-6.71,2.17) | 0.32 | -2.18 | (-5.98, 1.63) | 0.26 | |
| >40 | -2.17 | (-7.87, 3.54) | 0.46 | -7.31 | (-12.11, -2. 50) | 0.003 | |
| Sex | Female | 1.0 | 1.0 | ||||
| Male | -3.60 | (-8.22, 1.02) | 0.13 | -0.94 | (-4.98, 3.10) | 0.65 | |
| Baseline CD4 coimt (cells/μl) | >150 | 1.0 | 1.0 | ||||
| 100–149 | 3.85 | (-1.63, 9.33) | 0,17 | -2.17 | (-7.09, 2.76) | 0.39 | |
| 50–99 | 3.53 | (-1.84, 8.91) | 0.20 | 0.93 | (-4.22, 6.08) | 0.72 | |
| <50 | 2.34 | (-3.31, 7.98) | 0.42 | 8.55 | (2.39, 14.71) | 0.007 | |
| WHO clinical stage | 1 & 2 | 1.0 | 1.0 | ||||
| 3 | 1.79 | (-3.33, 6.91) | 0.49 | -0.70 | (-5.40, 4.00) | 0.77 | |
| 4 | 0.55 | (-5.39, 6.49) | 0.86 | -1.76 | (-6.93, 3.41) | 0.50 | |
| Baseline viral load (copies/ml) | <5 log10 | 1.0 | 1.0 | ||||
| >5 log10 | 11.14 | (7.10, 15.18) | <0.001 | 2.21 | (-1.37, 5.80) | 0.23 | |
1 The Phase 2 model included as covariates all variables shown, as well the phase 1 CD4 cell slope, the CD4 cell count at 16 weeks and the viral load at 16 weeks (see text).